Sales of the HIV drug Fuzeon dropped 9 percent in the fourth quarter of 2007 from the same period a year ago, Trimeris (Nasdaq: TRMS) reported Tuesday.

Sales dipped to $66.5 million in the quarter, down from $73.9 million in the previous three months. A sharp drop of 25 percent in the U.S. and Canadian market to $31.5 million offset a 13 percent increase for international sales to $35 million.

For the year, Fuzeon sales increased 7 percent to $266.8 million from $249 million in 2006.

Trimeris markets and sells the drug in partnership with Roche.